A pharmacological protocol for the management of medication-related osteonecrosis of the jaws: A randomized study
| ISRCTN | ISRCTN18375975 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN18375975 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | Nil known |
| Sponsor | Ospedale Generale Regionale Francesco Miulli |
| Funder | Ospedale Generale Regionale Francesco Miulli |
- Submission date
- 29/06/2023
- Registration date
- 06/07/2023
- Last edited
- 06/08/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Plain English summary of protocol
Background and study aims
Medication-related osteonecrosis of the jaws (MRONJ) is a challenging situation in clinics. Previous studies showed that pentoxifylline (PTX) combined with tocopherol was beneficial in patients with osteoradionecrosis, due to its antioxidant and antifibrotic properties. This study aims to evaluate the effect of PTX and tocopherol in patients with MRONJ.
Who can participate?
Female Stage I MRONJ patients with osteoporosis who had developed MRONJ after tooth extractions
What does the study involve?
The test group receives the pharmacological protocol with PTX and tocopherol (2 months pre-operatively and 6 months post-operatively). The control group has sequestrectomy operations (surgical removal of necrotic bone) without any pharmacological preparation. The main outcomes are clinical healing of the mucosa after 1 month and clinical and radiographic healing of the bone lesion at 6 months.
What are the possible benefits and risks of participating?
It is expected that in osteoporosis patients with Stage I MRONJ, the proposed pharmacological treatment with PTX and tocopherol will improve mucosal and bone healing rates and minimize relapses and complications, as compared to the control group.
The drugs used in the study are safe; pentoxifylline (PTX) is a methylxanthine derivate that was originally approved by the Food and Drug Administration (FDA) to treat peripheral artery diseases and has been used to treat complications related to fibrosis for over 20 years. PTX increases vasodilation and erythrocyte flexibility and reduces blood viscosity, which leads to an improvement in peripheral blood flow and tissue oxygenation. Tocopherols are organic chemical compounds consisting of various methylated phenols with beneficial effects. Tocopherols decrease tissue fibrosis, reduce inflammation, and have antioxidant effects that protect cell membranes from lipid peroxidation by reducing the free radical damage generated during oxidative stress. PTX in combination with tocopherol has a synergistic effect and is used for the management of osteoradionecrosis, with beneficial antioxidant and antifibrotic properties. The main risk for participants receiving the pharmacological treatment is that it is ineffective, and the chance of developing relapses or worsening the disease after the intervention remains high. No other risks other than those commonly associated with surgical intervention (e.g. post-operative bleeding, pain, swelling, infection) are foreseen.
Where is the study run from?
Department of Oral Surgery and Maxillofacial Surgery, Francesco Miulli Regional Hospital, University of Bari (Bari, Italy), and Oral Med Care srl, Regional Dental Medical Centre of Oral Surgery and Maxillofacial Surgery (Bitonto, Italy).
When is the study starting and how long is it expected to run for?
June 2013 to January 2023
Who is funding the study?
Francesco Miulli Regional Hospital (Generale Regionale Francesco Miulli) (Italy)
Who is the main contact?
Dr. Gianluca Colapinto, colapinto.gianluca@virgilio.it
Prof. Massimo Del Fabbro, massimo.delfabbro@unimi.it
Contact information
Principal investigator
Via Giuseppe Capaldi n 9
Bitonto
70032
Italy
| Phone | +39 (0)3887913143 |
|---|---|
| oralmedcaresrl@gmail.com |
Scientific
Department of Biomedical, Surgical and Dental Sciences, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano
Via della Commenda 10
Milano
20122
Italy
| Phone | +39(0)3496451220 |
|---|---|
| massimo.delfabbro@unimi.it |
Study information
| Primary study design | Other |
|---|---|
| Study design | Single-centre interventional randomized controlled trial |
| Secondary study design | |
| Study type | Participant information sheet |
| Scientific title | Effectiveness of a pharmacological protocol with pentoxifylline and tocopherol for the management of medication-related osteonecrosis of the jaws (MRONJ): A randomized study on 202 osteoporosis patients. |
| Study objectives | The aim is to verify that pharmacological treatment of preparation with pentoxifylline and tocopherol in patients affected by MRONJ and candidates for surgery, improves mucosal and bone healing rates compared to patients affected by MRONJ and candidates for surgery not undergoing pharmacological preparation. |
| Ethics approval(s) |
Approved 13/02/2014, Institutional Review Board of the Francesco Miulli Regional Hospital (Strada Prov. 127 Acquaviva – Santeramo Km. 4, 70021, 70021 Acquaviva delle Fonti BA, ACQUAVIVA delle FONTI, 70021, Italy; +39 (0)803054111; protocollo.miulli@legalmail.it), ref: 203077-13/02/2014 |
| Health condition(s) or problem(s) studied | Medication-related osteonecrosis of the jaws (MRONJ) in osteoporosis patients |
| Intervention | All patients are randomly divided into two groups, a test group and a control group, in a double-blind manner. The test group will receive the pharmacological preparation with pentoxifylline (600 mg x 2/day) and tocopherol (800 IU x 1/day) from 2 months before to 6 months after the surgical procedure, while the control group will directly receive the surgical procedure. The results will be evaluated and it will be verified whether the pharmacological preparation improves the results. |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Pentoxifylline, tocopherol |
| Primary outcome measure(s) |
1. Mucosal healing measured clinically by visual inspection at 1 week, 2 weeks, 1 month, 2, 6, and 12 months after the intervention |
| Key secondary outcome measure(s) |
The following secondary outcome measures will be observed yearly from 1 year up to 8 years: |
| Completion date | 31/01/2023 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Female |
| Target sample size at registration | 202 |
| Total final enrolment | 202 |
| Key inclusion criteria | Patients with osteoporosis and MRONJ stage I |
| Key exclusion criteria | 1. Cancer patients with metastatic bone disease 2. Other stages of MRONJ |
| Date of first enrolment | 01/08/2013 |
| Date of final enrolment | 01/11/2017 |
Locations
Countries of recruitment
- Italy
Study participating centres
Acquaviva delle Fonti
70021
Italy
Bitonto
70032
Italy
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Available on request |
| IPD sharing plan | Data analysed during the current study will be available upon request from Prof Massimo Del Fabbro (massimo.delfabbro@unimi.it) |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 13/07/2023 | 06/08/2024 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
06/08/2024: Publication reference added.
06/07/2023: Trial's existence confirmed by the Maxillofacial Surgery Department, Francesco Miulli Regional Hospital (Generale Regionale Francesco Miulli) (Italy).
